Health & Medication Blog
Evidence-based guides, comparisons, and practical advice for GLP-1 medications, TRT, HRT, mental health, and more. Updated regularly with the latest research, FDA news, and pricing.
ICOTYDE: FDA Approves First-of-Its-Kind Oral Psoriasis Pill
The FDA has approved ICOTYDE, the first-ever oral biologic for plaque psoriasis. Here is what the approval means and how it stacks up against injectable biologics.
Awiqli: FDA Approves First Once-Weekly Insulin for Type 2 Diabetes
The FDA approved Awiqli, the first once-weekly basal insulin, on March 26, 2026. Here is how insulin icodec works and who it is best for.
FDA Drug Approvals 2026: Complete Tracker of New Medications
Every novel drug the FDA has approved in 2026 so far — from oncology breakthroughs to the first oral psoriasis biologic. Updated regularly as new approvals are announced.
Upcoming FDA Drug Decisions 2026: PDUFA Dates to Watch
The biggest PDUFA dates remaining in 2026, from CagriSema to retatrutide to relutrigine. Here is what the FDA is expected to decide on and when.
Adquey (Difamilast): New FDA-Approved Treatment for Eczema
Adquey is a new topical PDE4 inhibitor approved for mild-to-moderate eczema. Here is how it compares to existing non-steroidal treatments and who should consider it.
Planning a medication switch?
Use our free calculator to get a personalized switching plan, dose mapping, and cost comparison.
Try the MedSwitcher CalculatorResearch without missing the move
Get the important GLP-1 updates, not more noise
We’ll send the high-signal stuff only: pricing changes, shortages, and new switch guidance worth acting on.
- Price and access changes
- New medication comparisons
- Actionable switch guidance
No spam. Unsubscribe anytime. We never share your email.